APA (7th ed.) Citation

RL, D., JG, K., LJ, S., GI, R., MA, V., LA, H., . . . ML, R. (1999). Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17(2), 685. https://doi.org/10.1200/JCO.1999.17.2.685

Chicago Style (17th ed.) Citation

RL, Drengler, et al. "Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients with Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 17, no. 2 (1999): 685. https://doi.org/10.1200/JCO.1999.17.2.685.

MLA (9th ed.) Citation

RL, Drengler, et al. "Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients with Solid Tumors." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 17, no. 2, 1999, p. 685, https://doi.org/10.1200/JCO.1999.17.2.685.